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Abstract 
Background: We examined the role of post-treatment symptoms and functional problems, 
and of worry about recurrent disease (WREC), in predicting and probable anxiety and 
depression cases 24 months after diagnosis in survivors of posterior uveal melanoma (UM). 
We examined whether WREC mediates links between symptoms, functional problems, and 
probable anxiety and depression cases. Methods: Prospective cohort study of 261 treated UM 
survivors 6, 12 and 24 months after diagnosis. Hierarchical logistic regression analyses 
predicting anxiety and depression 24 months after diagnosis identified by Hospital Anxiety 
and Depression Scale cut-off scores. Symptoms, functional problems and WREC 6 months 
post-treatment were entered into the analyses as predictors, then the same variables at 12 
months. We controlled anxiety or depression at 6 and 12 months and chromosome 3 status, 
which accurately predicts 10-year survival. Mediation of links between 6-month symptoms 
and functional problems and 24-month anxiety and depression by 12-month WREC was 
tested. Results: Anxiety caseness at 24 months was predicted by 6-month ocular irritation, 
headache and functional problems, and 12-month WREC. Depression caseness at 24 months 
was predicted by 6-month headache and functional problems. WREC at 12-months mediated 
prediction of anxiety caseness by 6-month symptoms and functional problems. Chromosome 
3 status predicted neither anxiety nor depression. Conclusions:. Survivors reporting 
symptoms, functional problems and WREC should be monitored for anxiety and depression. 
Appropriate reassurance that symptoms do not signify future disease might help prevent 
anxiety.  
 
Keywords: Cancer; Oncology: Uveal melanoma; anxiety; depression; cancer survivorship; 
worry about recurrence  
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Introduction 
Ten-year UK survival for all cancers is now estimated to be 50% compared to 24% 40 years 
ago [1]. Improved survival brings the problems of cancer survivorship into focus. In 
particular, between 15 and 26% of survivors experience clinically significant anxiety and 
depression three to five years following treatment [2-4].  
Research has focussed on anxiety and depression during diagnosis and treatment [5, 
6] but less so on long-term survivors a year or more after treatment. The main approach to 
understanding long-term anxiety and depression has been to try to predict these from clinical 
and psychological variables measured at baselines established soon after diagnosis or 
treatment. A recent review [7] shows that this approach has been largely unfruitful. Reliable 
predictors are baseline levels of anxiety and depression, personality variables such as 
neuroticism, and premorbid psychological problems. Whilst helping to identify potentially 
vulnerable patients, these findings offer limited insights for prevention or treatment. 
Premorbid conditions cannot be changed and neuroticism and trait anxiety are difficult to 
change, whilst short-term anxiety and depression are normal responses to a cancer diagnosis 
that often spontaneously remit [8, 9].  
Cancer, and its surgical, radiotherapy and chemotherapy treatments, can cause 
debilitating symptoms and consequent problems with day-to-day functioning [10, 11]. 
Symptoms often arise up to a year after treatment. Thus, symptom occurrence and any effects 
of those symptoms on anxiety or depression will not be captured in research that measures 
predictors shortly after diagnosis or treatment. Post-treatment symptoms and functional 
problems predict anxiety and depression symptoms in cross-sectional studies [2, 3], but cross-
sectional designs cannot show causality. We are not aware of prospective research that tests 
whether post-treatment symptoms and functional problems are linked to long-term anxiety 
and depression. 
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One reason why symptoms and functional problems might cause anxiety or 
depression is by inducing worry about recurrent disease (WREC), which, in turn, might lead 
to anxiety and depression. WREC is common amongst survivors, and usually arises months 
or years after diagnosis and treatment [12]. Symptoms and functional problems could induce 
WREC because they create fears of further disease, or because they remind patients of their 
recent cancer experience [13]. WREC has frequently been linked to anxiety and depression 
[12, 14], but again studies are cross-sectional so it is unclear whether WREC is a cause or a 
consequence of anxiety or depression.  
Prospective cohort studies examine temporal sequencing associations, providing 
stronger evidence of causality. The present study used a sample of uveal melanoma (UM) 
patients to examine whether patients’ reports of symptoms and functional problems predict 
later anxiety and depression caseness, identified by Hospital Anxiety and Depression Scale 
(HADS) cut-off scores. We also examined whether WREC mediates this relationship. UM 
provides an ideal model to investigate the influence of post-treatment symptoms on long-term 
anxiety and depression for two reasons. First, whilst patients experience pre-treatment visual 
symptoms in uveal melanoma, these symptoms are rarely debilitating [15, 16]. In contrast, 
post-treatment symptoms and functional problems, including impaired vision, ocular 
irritation and headaches, can be severe and are linked to anxiety and depression in cross-
sectional studies [17-19].  
Second, UM serves as a model to understand the origins and influence of WREC 
because risk of metastatic cancer recurrence can be accurately predicted. A limitation of most 
WREC research is that objective risks of cancer recurrence cannot be accurately determined 
[12]. Worry about recurrence should be understood in the context of objective risk. Worry 
that is proportional to risk can be considered rational, and interventions should help patients 
to manage the worry [20, 21]. Where worry is disproportionate to objective risk, intervention 
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goals should include challenging unrealistic or irrational beliefs about risk [12]. About 40-
50% of UM patients will develop metastatic disease within 10 years, for which treatment 
rarely prolongs life [22]. Metastatic disease develops almost exclusively in patients whose 
tumor shows chromosome 3 deletion (i.e., monosomy 3) [23, 24]. Patients are offered 
prognostic testing and informed of their prognosis if they accept it. Objective risk, 
(chromosome 3 status) can be statistically controlled, thus exposing any influence of 
subjective WREC on anxiety and depression.   
Aims  
Using a prospective cohort design in UM patients, our first aim was to determine whether 
impaired vision, ocular irritation, headaches, functional difficulties or WREC assessed 6 and 
12 months after diagnosis predicted probable anxiety and depression caseness, identified by 
the HADS, 24 months after diagnosis. Our second aim was to establish whether WREC at 12 
months mediates any prediction of 24-month anxiety or depression caseness by 6-month 
symptoms and functional problems.  
 
 Materials & Methods 
Participants 
This audit was approved by the Health Research Authority North West – Liverpool Central 
Ethics Committee (03/06/072/A) and conducted in accordance with the Declaration of 
Helsinki. The sample comprised a consecutive series of all adult patients treated for posterior 
uveal melanoma (choroid and ciliary body) between April 1
st
 2008 and December 31
st
 2011 
at the Liverpool Ocular Oncology Centre (LOOC). Diagnosis and treatment was based on 
clinical and tumor characteristics described by Damato and Heimann [25]. Most patients had 
ruthenium plaque radiotherapy or proton beam radiotherapy. If the tumor was unsuitable for 
radiotherapy, patients underwent trans-scleral local resection, trans-retinal endoresection or 
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enucleation (i.e., amputation) of the affected eye. Patients who consented to prognostic 
testing received verbal explanations of their results.  
 At diagnosis, patients were asked if they were willing to participate in an audit to 
examine long-term patient reported outcomes of treatment. Patients who gave written consent 
were posted questionnaires 6, 12 and 24 months following diagnosis with enclosed postage-
paid envelopes addressed to the researchers. 
Measures 
Demographic, clinical and treatment variables and chromosome 3 status were collected from 
patients’ clinical records. These included age, gender, relationship and employment status, 
whether right or left eye was affected, vision in the unaffected eye at diagnosis, tumour origin 
(choroid or ciliary body) and primary treatment type including whether the affected eye was 
conserved or removed. Prognostication was largely determined by chromosome 3 status [25]. 
Outcomes of testing were categorized as: monosomy 3, disomy 3 (i.e., normal maternal and 
paternal copies of chromosome 3) and unknown (comprising patients who did not wish to be 
tested and those whose genetic test failed). Dummy binomial variables were formed to allow 
comparisons between patients with monosomy 3 and disomy 3 and between patients with 
monosomy 3 and those whose chromosome 3 status was unknown. 
Cut-off scores of ≥8 on anxiety and depression subscales of the HADS [26] were used 
to identify potential cases. A recent meta-analysis comparing HADS cut-offs to structured 
interview diagnoses [27] showed the anxiety cut-off of 8 or greater to predict either anxiety 
or depression with a sensitivity of .73 and specificity of .65. The same cut-off for depression 
predicts depressive disorders with a sensitivity of .86 and specificity of .81 [27].  
Post-treatment symptoms and functional problems were measured using the European 
Organisation for Research and Treatment for Cancer Ophthalmic Quality of Life Module 
(QLQ-OPT 30 [28]), validated in UM samples [29]. Subscales related to specific treatments, 
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such as enucleation, or to activities engaged in by subsets of participants, such as driving, 
were disregarded. Subscales were: ocular irritation, a 6-item scale with a Cronbach alpha in 
our sample of .71 at 6 months and .75 at 12 months; vision impairment, a 4-item scale with 
an alpha of .69 at 6 months and .73 at 12 months; a single item measuring headache, and 
functional problems a 6-item scale with an alpha of .92 at both 6 and 12 months. 
The QLQ-OPT 30 has a 4-item WREC scale. An item on concern about loss of the 
eye was disregarded. The remaining three items were used, with an alpha of .87 at 6 months 
and .85 at 12 months. Response format for all QLQ-OPT 30 items is ‘Not at all’, ‘A little’, 
‘Quite a bit’ and ‘Very much’, scored 1-4, respectively.  Higher scores indicate poorer 
outcomes.  
Statistical analysis  
Preliminary analyses determined whether demographic, clinical and treatment variables, in 
addition to Chromosome 3 status needed to be statistically controlled. We used Pearson and 
point-biserial correlations to test whether these variables predicted 24-month anxiety and 
depression, and conducted interaction analyses to test whether they moderated any 
associations between predictor variables and 24-month anxiety and depression. Multivariate 
analyses then examined whether symptoms, functional problems and WREC at 6 and 12 
months predicted 24-month anxiety and depression cases. Mediation analysis tested whether 
WREC at 12 months mediated the prediction of anxiety and depression caseness at 24 months 
by symptoms and functional problems at 6 months. 
Prediction of anxiety and depression caseness at 24 months: Two hierarchical multivariate 
logistic regression analyses were conducted. Logistic regression provides simple and accurate 
odds ratio estimation for binary outcomes (30). Objective risk (Chromosome 3 status) and 
anxiety or depression at 6 & 12 months, were entered as statistical control variables in the 
first block. Demographic, clinical and treatment variables were entered as control variables in 
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this block if they were associated with 24-month anxiety or depression in preliminary 
analyses. The second block comprised 6-month symptoms, functional problems and WREC. 
The third block comprised 12-month symptoms, functional problems and WREC. 
Multivariate prediction was tested using odds ratios with 95% confidence intervals.  
Mediation analysis: Change scores in WREC from 6 to 12 months were computed, as were 
changes in anxiety and depression caseness between 12 and 24 months. Potential mediation 
of 12-24 month changes in anxiety and depression caseness by 6-12 month changes in WREC 
was tested using bias-corrected and accelerated bootstrapping [31]. Mediation was separately 
tested for each symptom and the functional problem score. Anxiety or depression caseness at 
12 months and WREC at 6 months were controlled in these analyses. 
Sample Attrition: This was assessed using multivariate logistic regression to predict the 
likelihood of retention at 24 months from 6-month demographic, clinical and treatment 
variables, chromosome 3 status, symptoms and functional problems, WREC, and depression 
and anxiety caseness. 
 
Results 
Of 716 patients who were asked to take part, 554 (77.4%) consented and 411/554 (74.2%) 
returned 6-month data, 325 returned 12-month data and 291 returned 24-month data. 261 
(63.5% of the 411 returned at 6 months) returned data at all three follow-up points and were 
used in the analysis. Socio-demographic and clinical characteristics are shown in Online 
Supplement 1
1
. Bivariate analyses showed that female gender and younger age predicted 24-
month anxiety and depression caseness. These, as well as chromosome 3 status and 6 and 12-
month anxiety or depression caseness were used as covariates in the multivariate analyses.  
                                                          
1
 Associations between predictor and outcome variables cases were not significantly moderated by 
demographic variables or Chromosome 3 status 
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Table 1 shows anxiety and depression caseness and symptom, functional problem and 
WREC scores at 6, 12 and 24 months. Associations between them are available in Online 
supplement 2. Positive associations were generally observed amongst symptoms, functional 
problems, WREC and anxiety and depression caseness within each time-point and between 
time-points. 6-month symptoms and functional problems were associated with greater 12-
month WREC and a greater likelihood of 24-month anxiety and depression caseness. 12-
month WREC was associated with a greater likelihood of 24-month anxiety and depression 
caseness. 
 
Prediction of anxiety and depression at 24 months 
Table 2 shows multivariate predictors of anxiety and depression cases after entry of each 
predictor block. After entry of the first block, 6 and 12-month anxiety or depression caseness 
were the only significant predictors; chromosome 3 status predicted neither anxiety nor 
depression. After including the putative predictor variables measured at 6 months in block 2, 
ocular irritation, headache and functional difficulties each uniquely predicted anxiety 
caseness. Headache and functional problems predicted depression caseness. WREC at 6 
months did not predict anxiety caseness, but predicted a lower probability of depression 
caseness. After including the predictor variables measured at 12 months in block 3, no 
variable predicted depression caseness. WREC at 12 months predicted anxiety. Analyses 
show that the symptoms and functional problems that predict anxiety and depression caseness 
at 24 months emerge within 6 months of diagnosis, and that WREC associated with long term 
anxiety caseness arises between 6 and 12 months
2
.  
                                                          
2
 Multicollinearity is problematic when measures are repeated. Tolerances were generally about 0.50 with 
the lowest tolerances observed for functional problems at 6 (Tolerance=0.29) and 12 months 
(Tolerance=0.25). These do not constitute problematic levels of multicollinearity [33]. No adjustments 
were made to the analyses.   
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 Inverse prediction of 24-month depression from 6-month WREC was not expected, 
with no evidence of univariate prediction. This indicates a possible multivariate suppression 
effect [32]. On further examination, 6-month headache and functional problems no longer 
predicted 24-month depression when 6-month WREC was removed. This supports a 
suppressor interpretation - 6-month WREC suppresses criterion-irrelevant variance in other 
predictors but has no inherent association with 24-month anxiety. 
 
Mediation analyses 
Table 3 shows the outcomes of mediation analyses. WREC changes toward increased worry 
from 6 to 12 months mediated the prediction of an increased likelihood of anxiety caseness 
from 12 to 24 months by headache at 6 months. Mediation effects approaching significance 
were noted for ocular irritation and functional problems at 6 months.  
 
Sample Attrition 
Sample attrition analysis showed no evidence of attrition bias. The logistic regression 
predicting whether patients dropped out or were retained at 24 months from 6-month study 
variables did not show significant prediction (2=21.00, df=21, p=.269). 
 
Discussion 
Our first aim was to identify predictors of anxiety and depression. Patients who reported 
symptoms and functional problems 6 months after diagnosis were more likely to score above 
HADS caseness cut-offs for anxiety or depression. Those reporting worry about recurrent 
disease at 12 months were more likely to be above anxiety cut-offs at 24 months.  The second 
aim was to prospectively test the hypothesis that 12-month worry about recurrence could 
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mediate the relationship between symptoms at 6 months and anxiety and depression at 24 
months. This hypothesis was supported for anxiety only. 
Findings are consistent with cross-sectional studies in UM [17- 19] and other cancers 
[2, 3], but provide stronger evidence that symptoms, functional problems and WREC could 
cause anxiety and depression because we show that these precede, and thus cannot be 
consequences of, anxiety and depression. The finding that 12-month WREC predicts 24-
month anxiety is also consistent with cross-sectional evidence [20, 34]. We can be specific 
about the timeframe. WREC at 6 months did not predict 24-month anxiety, demonstrating 
that prediction of anxiety is attributable to worry that emerges between 6 and 12 months. To 
our knowledge, this is the first study to show that worry about disease recurrence mediates 
effects of symptoms and functional problems on anxiety. Our claim for mediation is 
strengthened by the prospective design, which eliminates the possibility that any part of the 
meditational sequence occurs in reverse.  
Previous cross-sectional studies show associations between WREC and both anxiety 
and depression [12, 14]. Our prospective analyses showed WREC to predict only anxiety, 
suggesting that WREC might cause future anxiety but probably does not cause depression. 
Worries about recurrence are commonly conceptualized within an anxiety framework [12, 
21], and these findings provide empirical support for the idea that WREC is predominantly a 
risk for anxiety.  
WREC predicted anxiety after controlling chromosome 3 status. Thus, worry about 
disease recurrence cannot be accounted for by objective risk of recurrence. Although worry is 
suspected to be independent of objective risk [12], our study is the first to statistically control 
recurrence (i.e., metastasis) risk. Consistent with previous UM research [35], chromosome 3 
status itself did not influence anxiety or depression.  
 
  
This article is protected by copyright. All rights reserved. 
Limitations 
Although our prospective design strengthens claims of causality, we cannot fully eliminate 
alternative causal models. For example, patients’ perceptions of symptoms and functional 
problems are subjective, and it is possible that a greater sensitivity to symptoms and 
functional problems represent early manifestations of anxiety and depression and do not 
cause it [36]. Also, effects of unmeasured variables cannot be controlled.  Another limitation 
is that we did not take a pre-treatment baseline, and are unaware of the extent to which 
symptoms such as headaches, existed before diagnosis and treatment. However, we 
statistically controlled anxiety and depression at 6 months. Thus, it is unlikely that pre-
treatment symptoms or functional impairments could influence anxiety or depression at 24 
months without influencing these variables at 6 and 12 months. We monitored patients for 24 
months, and thus cannot safely make inferences about a longer time period. Nonetheless, our 
findings are unlikely to represent transient effects because at least 18 months elapsed between 
measuring 6-month symptoms and functional problems and recording 24-month anxiety and 
depression. HADS scales are commonly used to find probable anxiety and depression 
caseness. They have good sensitivity and specificity, but do not provide definitive diagnoses. 
Findings need to be considered in the context of attrition of 36.5% of the sample. Although 
attrition analyses showed little bias, bias may exist in unmeasured variables. Last, we did not 
collect information on socioeconomic status or ethnicity. 
 
Research and Clinical Implications  
The key finding is that post-treatment symptoms, functional problems and WREC precede, 
and possibly contribute to, long-term anxiety and depression in cancer survivors. Thus, a 
greater focus on the impact of post treatment events on the development of long-term anxiety 
and depression is warranted. Symptoms and functional problems observed in this study are 
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not amenable to medical or surgical interventions, thus approaches to prevention and 
treatment will need to be psychological.   
Mediation by WREC demonstrates a specific psychological process, but our findings 
do not explain (1) why patients worry when they experience symptoms and functional 
problems, (2) which specific aspects of symptoms and functional problems cause worry, or 
(3) which patients are likely to be at risk. WREC is likely to be underpinned by the specific 
interpretations that patients make. For example, a study of breast cancer survivors [13] 
suggests that patients may see symptoms and functional problems as early manifestations of 
recurrent disease or as reminders of feelings of risk or vulnerability associated with their 
cancer experience.  
Mediation was only partial. Symptoms and functional problems predicted anxiety and 
depression independently of WREC. It is important to understand why patients’ experiences 
of symptoms and functional problems directly increase risks of long-term anxiety and 
depression. One possibility is that symptoms and functional problems cause pain and 
discomfort that impair daily living over a long time period. The adverse effects of chronic 
pain and discomfort on long-term anxiety and depression are well established [37], and will 
need to be treated with support and therapeutic programs [38, 39].  
In terms of clinical implications, the focus of attention during follow-up should be on 
preparing patients to better understand and cope with symptoms and functional problems. 
This has two immediate implications. First, patients who report concerns about symptoms, 
functional problems and worry about recurrence should be monitored for early signs of 
psychological distress. Second, it is important that patients be reassured that symptoms 
probably do not portend future disease. The final implication is the finding that informing 
patients of their chromosome 3 status does not influence anxiety or depression. This assuages 
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concerns that patients may be psychologically harmed, at least in terms of anxiety or 
depression, by adverse prognoses about metastatic disease.  
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Table 1. Psychological and Somatic Variables at Post Diagnosis Observations. N=261. 
Prevalences of HADS Anxiety and Depression Cases  
 6 months  12 months 24 months 
 N Percent N Percent N Percent 
Anxiety ‘case’ 70 26.8 67 27.7 59 22.6 
Depression ‘case’ 26 10.1 30 11.5 30 11.5 
Scale Ranges, Means and SDs for Predictors 
 Scale Range Mean SD Mean SD Mean SD 
Ocular Irritation 6-24 9.68 3.14 9.70 3.17 9.76 3.31 
Visual Impairment 4-16 6.13 2.44 6.08 2.61 5.87 2.39 
Headache 1-4 1.57 0.83 1.56 0.82 1.52 0.80 
Functional problems 6-24 10.02 4.33 9.89 4.21 9.94 4.23 
Worry Recurrent Disease 3-12 7.30 2.71 6.56 2.51 6.29 2.41 
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Table 2 Multivariate Predictors of 24-Month HADS Anxiety and Depression Cases 
Using Binomial Logistic Regression 
 Anxiety Depression 
 
Model Fit 
Χ2(14)=128.17 
Cox-Snell R
2
=0.396 
89.4% classification 
Χ2(14)=75.98 
Cox-Snell R
2
=0.253 
94.3% classification 
Predictors 
 Lower 95% 
C.I. 
 
Odds ratio Upper 95% 
C.I. 
Lower 95% 
C.I. 
 
Odds ratio Upper 95% 
C.I. 
Block 1 Covariates
Ϯ
  χ2=97.6**   χ2=60.7*  
  Age 0.99 1.02 1.05 0.95 0.99 1.03 
  Sex 0.38 0.86 1.96 0.21 0.61 1.77 
  6 month Anxiety/Depression 4.08 9.86* 23.86 3.42 12.06* 42.59 
  12 month Anxiety/Depression 3.33 7.56* 17.15 3.19 9.94* 30.97 
  M3 (1) 0.24 0.71 2.07 0.50 1.78 6.40 
  M3 (2) 0.11 0.43 1.65 0.21 1.06 5.30 
Block 2: 6 -month   χ
2
=16.1**   χ2=17.7*  
  Ocular Irritation 1.04 1.23* 1.45 0.93 1.13 1.37 
  Visual Impairment 0.78 0.97 1.22 0.65 0.85 1.08 
  Headache 1.07 1.77* 2.95 1.10 2.32* 4.92 
  Functional problems 1.00 1.12* 1.25 0.91 1.16* 1.34 
  Worry Recurrent Disease 0.84 1.01 1.21 0.54 0.71* 0.93 
Block 3: 12-month   χ
2
=9.69*   χ2=1.6  
  Ocular Irritation 0.73 0.89 1.11 0.83 1.06 1.34 
  Visual Impairment 0.82 0.97 1.24 0.66 0.93 1.31 
  Headache 0.86 1.64 3.17 0.71 1.47 3.04 
  Functional 0.80 0.97 1.18 0.77 0.98 1.24 
  Worry Recurrent Disease 1.04 1.34* 1.73 0.71 1.01 1.42 
 
Ϯ
 Odds ratios and C.I.s are those observed after entry of each block.; *p<.05; **p<.01 
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Table 3: Bootstrapping Estimates of the Indirect Effect of 6 Month Symptoms and Functional 
Problems on 12-24 month Changes on HADS Anxiety Cases Mediated by Changes in 6-12 
Month Worry about Recurrence. 
 
 Corrected 
Estimate 
SE Lower 
95% 
Higher 95% 
 6 month Ocular Irritation .0020
Ϯ
 .0016 -.0002 .0064 
 6 month Visual Impairment .0005 .0006 -.0035 .0052 
 6 month Headaches .0115 .0000 .0010 .0326 
 6 month Functional Problems .0027 .0001 -.0003 .0078 
Ϯ
 Unstandardized beta estimates. 
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Figure 1: Standardised Beta Coefficients for the Indirect Effect of 6 Month Symptoms and 
Functional Problems on 12-24 month Changes in HADS Anxiety Caseness Mediated by 6-12 
Month Changes in Worry about Recurrence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 month Ocular 
Irritation 
6-12 month ∆ 
WREC 
12-24 month ∆ 
Anxiety 
.070 .039* 
.027* (.029*) 
6 month Visual 
Impairment 
6-12 month ∆ 
WREC 
12-24 month ∆ 
Anxiety 
.014 .033* 
.012 (.013) 
6 month Headaches 
6-12 month ∆ 
WREC 
12-24 month ∆ 
Anxiety 
.349* .029* 
.093* (.105*) 
6 month Functional 
Problems 
6-12 month ∆ 
WREC 
12-24 month ∆ 
Anxiety 
.109* .025* 
.015* (.018*) 
